Zacks Investment Research on MSN17d
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time frame, as ...
STAT1d
Alnylam enters the ATTR-CM drug race
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
Novo Nordisk Stock Rises Ahead of Data on Ozempic Ingredient's Ability to Lower Heart Risk
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
FiercePharma15d
With blood and growth disorder bids panning out, Novo Nordisk plots path to rare disease leadership: exec
Novo Nordisk's rare disease ambitions first began ... Forma Therapeutics in 2022 and its acquisition of 2seventy bio’s hemophilia A program in 2024. To date, Novo’s focus in rare disease ...
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How Novo Nordisk plays its ‘Ace’ in China's ‘Weight Management Year’
As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...
Medscape5d
Can Six Shots a Year Keep Hemophilia Bleeding Away?
Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg once every 2 months, individually adjusted to 20, 50, or 80 mg monthly or 20 ...
Why Novo Nordisk (NVO) is a Top Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.